The MAPK pathway, initiated by RTKs like EGFR and HER2, activates downstream effectors such as RAS, RAF, MEK, and ERK1/2, driving cell growth and survival. HER2 amplification further drives ...
Further tests confirmed the result. The signalling cascade downstream of EGFR includes proteins such as RAS, RAF, MEK and ERK. Activation of EGFR by epidermal growth factor (EGF) leads to ...
The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...
Combined MEK and PI3K inhibition has had limited success in the clinic, although alternative methods of targeting these pathways may be effective. MEK inhibitors form the backbone of multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback